In a recent study by You et al., KMT2D non-synonymous mutations have been shown to correlate with an overall increase in mutational burden in DLBCL, which intriguingly corresponded with low intra-tumoral T-cell infiltration in GCB DLBCL patients with WT P53 (You et al., 2021). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.